Get started
ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1 (USD)ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1 (USD)ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1 (USD)

ELI LILLY AND COMPANY CEDEAR EACH 56 REP 1 (USD)

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

LLYD trade ideas

Eli Lilly Stock Down 10.9% Over Past YearTop or Consolidation? Here's My Take... It's not crystal clear — I can see the case for both. But after years of chart-watching, this doesn't quite look like a top to me: • Lacks symmetry • Had chances to break down, but no real follow-through 🧭 Where are we headed? I think pressure remains, and we could dip toward the 50% retracement of the 2023 move — that’s around 646. 🔁 If we bounce from there, I’ll shift my bias to a recovery and resumption of the long-term uptrend. Disclaimer: The information posted on Trading View is for informative purposes and is not intended to constitute advice in any form, including but not limited to investment, accounting, tax, legal or regulatory advice. The information therefore has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. Opinions expressed are our current opinions as of the date appearing on Trading View only. All illustrations, forecasts or hypothetical data are for illustrative purposes only. The Society of Technical Analysts Ltd does not make representation that the information provided is appropriate for use in all jurisdictions or by all Investors or other potential Investors. Parties are therefore responsible for compliance with applicable local laws and regulations. The Society of Technical Analysts will not be held liable for any loss or damage resulting directly or indirectly from the use of any information on this site.
NYSE:LLY
by The_STA
Eli Lillly $LLYNYSE:LLY – Long Setup Ahead of June FOMC Eli Lilly remains fundamentally strong, with robust growth in revenue (+45% YoY), driven by weight-loss and diabetes drugs like Mounjaro and Zepbound. Despite this, the stock saw a recent pullback after a lowered FY25 profit outlook. Technical View: LLY is trading near a key support zone around $710. The setup offers a favorable 1:5 risk/reward ratio, with a stop at $700.86 and a target near $768. Bollinger Bands are tightening, indicating a potential breakout. This decline could be partially driven by market caution ahead of the upcoming FOMC meeting in June. If support holds, we may see a bounce toward the $760–770 area. Plan: Entry: ~$710 Target: ~$768 Stop: ~$700.86 Risk/Reward: 1:5 Watching price action closely near the lower Bollinger band.
NYSE:LLYLong
by ALVO13_official
Can Lilly Redefine Weight Loss Market Leadership?Eli Lilly is rapidly emerging as a dominant force in the burgeoning weight loss drug market, presenting a significant challenge to incumbent leader Novo Nordisk. Lilly has demonstrated remarkable commercial success despite its key therapy, Zepbound (tirzepatide), entering the market well after Novo Nordisk's Wegovy (semaglutide). Zepbound's substantial revenue in 2024 underscores its rapid adoption and strong competitive standing, leading market analysts to project Eli Lilly's obesity drug sales will surpass Novo Nordisk's within the next few years. This swift ascent highlights the impact of a highly effective product in a market with immense unmet demand. The success of Eli Lilly's tirzepatide, the active ingredient in both Zepbound and the diabetes treatment Mounjaro, stems from its dual mechanism targeting GLP-1 and GIP receptors, offering potentially enhanced clinical benefits. The company's market position was further solidified by a recent U.S. federal court ruling that upheld the FDA's decision to remove tirzepatide from the drug shortage list. This legal victory effectively halts compounding pharmacies from producing unauthorized, cheaper versions of Zepbound and Mounjaro, thereby protecting Lilly's market exclusivity and ensuring the integrity of the supply chain for the approved product. Looking ahead, Eli Lilly's pipeline includes the promising oral GLP-1 receptor agonist, orforglipron. Positive Phase 3 trial results indicate its potential as a convenient, non-injectable alternative with comparable efficacy to existing therapies. As a small molecule, orforglipron offers potential advantages in manufacturing scalability and cost, which could significantly expand access globally if approved. Eli Lilly is actively increasing its manufacturing capacity to meet anticipated demand for its incretin therapies, positioning itself to capitalize on the vast and growing global market for weight management solutions.
NYSE:LLYLong
by UDIS_View
Eli Lilly (LLY) Shares Fall Over 15% in MayEli Lilly (LLY) Shares Fall Over 15% in May The share price of Eli Lilly and Company (LLY), the world’s largest pharmaceutical company, has seen a sharp shift in market sentiment: → From its April low to high, LLY shares rose by over 30%; → However, since the start of May, the LLY stock price has dropped more than 15% — the closing price on the last trading day of April was around $895, while today the share is trading near $775. Why Are Eli Lilly (LLY) Shares Falling? The decline can be attributed to three key factors: 1→ Q1 Earnings Report: Although the company reported earnings per share above expectations ($3.34 vs $3.25), investors may have been concerned by significantly higher spending on research and development. 2→ Competitor Partnership: CVS Health’s announcement that it will offer Novo Nordisk’s Wegovy instead of Lilly’s Zepbound added further pressure to LLY shares. 3→ Sector Sentiment: Broader biotech sentiment turned negative following reports that the Trump administration is considering a pricing model that would cap drug prices based on lower rates in other countries. The media is also discussing upcoming decisions from Vinay Prasad, the new head of the FDA division overseeing vaccines and gene therapy. Technical Analysis: Eli Lilly (LLY) Share Chart Key price movements (marked on the chart) justify the formation of a downward channel. On the one hand, bearish sentiment may intensify in light of recent developments. The median line of the channel could act as resistance to any upward movement. On the other hand, bulls may find support around the $765 level — a former resistance point and the boundary between two price gaps. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NYSE:LLY
by FXOpen
LLY possible buy trend This chart highlights a recent price breakout followed by a pullback into consolidation. Key indicators in play: ✅ EMA 9/20/56: Price is currently trading below all EMAs, showing fading momentum. The EMAs are curling down, suggesting short-term weakness or cooling after a strong move. 🟣 SMA 50 & 200: Price is sitting below both the 50-SMA and 200-SMA, indicating a bearish or neutral mid- to long-term setup. The flattening 200-SMA may act as a long-term base. 📉 VWAP (not shown but implied): Price is likely trading below VWAP, reinforcing the intraday bearish bias and low-volume consolidation. 📐 Support & Resistance Levels: Blue horizontal lines mark recent support/resistance flips, providing key zones to watch for a breakout or breakdown. 🧠 Outlook: Current price action suggests a cool-down after a vertical run-up, with EMAs potentially acting as short-term resistance. Watching for a bounce off horizontal support or a move above the EMAs to confirm trend continuation.
NYSE:LLYLong
by MyGolfBudget
Eli Lilly: Catch the Knife or Wait for Support?LLY Just Dropped — Opportunity or Trap? 🔥 LLY (Eli Lilly) is on every trader’s radar! With biotech momentum and blockbuster drug potential, this stock is ready to rip once the dust settles. Smart money is eyeing key zones for a golden entry. 💊📈 📉 New Entry Zones: 🔥 630.00 – Solid buy level 🔥 550.00 – Strong value zone 🔥 465.00 – Deep discount opportunity (load-up zone!) 🎯 Profit Targets: ✅ 730.00 📈 (First leg up) ✅ 800.00 🚀 (Breakout zone) ✅ 900.00+ 💰 (All-time high chase) 💡 Volatility creates opportunity. LLY is a beast in the pharma game—any dip could set up a powerful bounce. Watch for heavy accumulation and reversal signals near those buy zones! 🚀 Ready to ride the next wave? LLY’s runway is long and the upside is juicy! #LLY #PharmaStocks #BuyTheDip #GrowthPlays 📌 Disclaimer: Not financial advice. Do your own research and consult with a professional before investing. 🔎💼
NYSE:LLYLong
by Robert_V12
ELI LILLY: The time to buy and target 1,300 is now.Eli Lilly is neutral on its 1D technical outlook (RSI = 48.409, MACD = -5.160, ADX = 28.927) and this is technically the most efficient level to buy for the long term towards the end of the year, as the price is sitting around its 1W MA50. The macro pattern is a Channel Up starting back in March 2019 and every time this broke under the 1W MA50 (but remained supported above the 1W MA100) and consolidated, it was the most efficient long term buy signal. In 6 years this has only happened 4 times and all those times the 1W RSI hit the 38.750 S1 level. The immediate target of all bullish waves that started after such bottoms, has been the 2.0 Fibonacci extension. Go long, TP = 1,300. ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope
$LLY Long-Term BuyHealthcare could possibly be the next rotation coming out of this tech bull run. Using the Trade Jeanie (Jeanius Screener/Indicator), I was able to see the current technical buy signals happening on NYSE:LLY : Inside a HTF fair value gap (3M timeframe) Took out an untested low (liquidity) The Jeanius Indicator shows green 'Combo' labels every time this same combination of signals happened The Jeanius Screener lets me filter my favorite tickers to see which ones are currently taking out untested lows or liquidity
NYSE:LLYLong
by jeanius_tech
LLY: Strong Buy in My Radar List - Feb. 26Technical Analysis (TA) & Price Action Eli Lilly (LLY) is showing strong bullish momentum, currently trading within an ascending channel on the 1-hour timeframe. The stock recently tested the upper trendline and is consolidating near $900, a key psychological level. Key observations: * Trend Structure: LLY is in a strong uptrend, forming higher highs and higher lows within a well-defined price channel. * Support & Resistance: * Major Resistance: $912 (recent high) * Key Support: $894, followed by $881 * Stronger Support Zones: $869 - $865 (confluence with PUT walls) * MACD Indicator: Bullish momentum persists but shows slight signs of cooling off. Watch for potential continuation. * Stoch RSI: Approaching overbought conditions, which may signal a slight pullback before another push higher. Options Flow & GEX Analysis The GEX (Gamma Exposure) indicator suggests a high call concentration around $900, aligning with our price action resistance. This means market makers may hedge aggressively if LLY sustains above this level, fueling further upside. * IVR (Implied Volatility Rank): 19, with IVx avg at 32.7%, indicating relatively lower volatility. * Call Side Bias: 23.4% of total options flow supports a bullish breakout scenario. * Key GEX Levels: * Strongest Resistance / CALL Wall: $900 → Break and hold here unlocks $920 (2nd CALL Wall). * PUT Support Zone: $865 - $867.5 → A breakdown could trigger downside hedging, making this a critical level to hold. Trade Plan & Suggestions 📌 Bullish Trade Setup (Preferred Play) * Entry: Above $900 with confirmation (sustained hold above resistance). * Target 1: $912 * Target 2: $920 (CALL Wall target) * Stop-loss: Below $894 📌 Bearish Alternative (Hedge Play) * Entry: Below $894 with volume breakdown. * Target: $881 → $869 * Stop-loss: Above $900 Final Thoughts LLY is one of the strongest setups on my radar. If it maintains above $900, it could trigger a gamma squeeze toward $920. However, failure to hold this level could result in a retest of $865-$869. Options positioning suggests a bullish bias, but watching price action closely is key. 📢 Risk Management: Always size positions according to your risk tolerance. Trade the setup, not the expectation. 🔹 Disclaimer: This analysis is for educational purposes only and does not constitute financial advice. Always conduct your own research and manage risk accordingly before trading.
NYSE:LLYLong
by BullBearInsights
Eli Lilly (LLY): Potential Continuation of UptrendLLY remains an under-the-radar stock that appears poised for a continuation of its upward trajectory. Following strong earnings and solid net income in the last quarter, analysts have revised their price targets upward, with some projections reaching as high as $1,000. This suggests a potential return of at least 10%. From a technical perspective, LLY has posted gains for the week and remains above the 20, 50, and 100-day simple moving averages (SMAs). After reporting positive earnings earlier this month, the stock has undergone a period of consolidation and now appears to be positioning for a breakout. Additionally, the current price action is clearing the gap created by the earnings-induced decline in November of last year. With prices breaking out and successfully retesting support, I anticipate a potential upside target of at least $945.
NYSE:LLYLong
by shidiq
ELI LILLY ahead of a 1D Golden Cross targeting $1225Last time we looked at Eli Lilly (LLY) 3 months ago (November 21 2024, see chart below), we've identified the bottom of its 5-year Channel Up and issued a strong long-term buy signal: Now we are upgrading our Target as the price action turned out to be very similar to the 2nd half of 2020, at the end of which the company witnessed strong growth. As you can see both 2020 and 2024 patterns have been correction phases in the form of Channel Downs. Even their 1D RSI sequences are similar. A 1D Death Cross paved the way for the bottom soon after and a 1D Golden Cross (Jan 11 2021) confirmed the start of a new phase of growth. The price is now above the 1D MA200 (orange trend-line) and if it continues to replicate 2021, then we expect this to be a Bullish Leg that will target the 1.786 Fibonacci extension. Our long-term Target now goes from $1135 to $1225. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot